Who is sponsoring NCT02985242?

NCT02985242 is sponsored by Hannover Medical School.

What condition does NCT02985242 study?

NCT02985242 studies Diabetes Mellitus, Type II.

What drugs are being tested in NCT02985242?

Interventions: Empagliflozin, Glimepiride, Empagliflozin placebo, Glimepiride placebo.

What is the status of NCT02985242?

NCT02985242 is currently TERMINATED.

Last reviewed 2018-09-27 · How we verify

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

NCT02985242 PHASE4 TERMINATED

This is a prospective, randomized, active control, two-arm parallel, double-blind, monocenter phase IV clinical trial. The trial compares empagliflozin to glimepiride in patients with type 2 diabetes mellitus in addition to standard of care treatment. Patients with type 2 diabetes mellitus who are between 18 and 80 years of age will be recruited for the clinical trial and randomly allocated to either receive empagliflozin or glimepiride. The assumption of the study is that empagliflozin slows down diabetic retinopathy progression rate and thus a lower microaneurysm formation rate compared to subjects treated with glimepiride by substantially decreased cellular glucotoxicity will be achieved.

Details

Lead sponsor	Hannover Medical School
Phase	PHASE4
Status	TERMINATED
Enrolment	6
Start date	Mon Jun 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Diabetes Mellitus, Type II

Interventions

Empagliflozin
Glimepiride
Empagliflozin placebo
Glimepiride placebo

Countries

Germany